Phase1study of a combination of CPT-11 and TS-1 and bevacizumab in patients with metastatic colon cancer
收藏NIAID Data Ecosystem2026-03-06 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2616713
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: We use three drugs (CPT-11, TS-1, bevacizumab) for this trial. The treatment schedule of CPT-11 and bevacizumab are administrated on day 1 and day 15, and of TS-1 is administrated between day1 and day 21. The dosage of CPT-11 are 80-110/m2, and of TS-1 are 80-120mg (the dosage are calculated by body surface area), and of bevacizumab are 5 or 7mg/kg.
Primary outcome(s): safety
Study Design: Single arm Non-randomized
创建时间：
2008-05-15
